Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 19, 2015 6:10 PM ET


Company Overview of Horizon Pharma plc

Company Overview

Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. It offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; PENNSAID for the treatment of pain of OA ...

Connaught House

1st Floor

1 Burlington Road

Dublin,  4


Founded in 2005

535 Employees


353 1 772 2100

Key Executives for Horizon Pharma plc

Chairman, Chief Executive Officer and President
Age: 47
Total Annual Compensation: $982.3K
Chief Financial Officer and Executive Vice President of Finance
Age: 49
Total Annual Compensation: $210.9K
Chief Business Officer and Executive Vice President
Age: 55
Total Annual Compensation: $492.0K
Chief Medical Officer and Executive Vice President of Research & Development
Age: 59
Total Annual Compensation: $396.3K
Chief Commercial Officer and Executive Vice President
Age: 46
Total Annual Compensation: $194.5K
Compensation as of Fiscal Year 2014.

Horizon Pharma plc Key Developments

Horizon Pharma Seeks Acquisitions

Horizon Pharma plc (NasdaqGS:HZNP) is planning to sell 12 million ordinary shares in an underwritten public offering. Horizon Pharma will use the proceeds to fund a portion of acquisition of Hyperion Therapeutics by the company and the remainder to fund additional acquisitions or investments in businesses, products and product candidates that are complementary to the company, and for general corporate purposes.

Horizon Pharma plc, Hyperion Therapeutics, Inc. - M&A Call

To review definitive agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Hyperion's common stock for $46.00 per share in cash or approximately $1.1 billion on a fully diluted basis and related matters

Horizon Pharma Mulls Acquisitions

Horizon Pharma plc is seeking acquisitions. Bob Carey, Executive Vice President and Chief Business Officer of Horizon Pharma plc said in Horizon Pharma Call, “We remain well positioned to drive revenue, and we will continue to seek additional acquisition opportunities to further leverage our business model and optimize our commercial infrastructure.”

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Horizon Pharma plc, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at